| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
In vivo experiment, citrate was increased, and pyruvate, succinate, fumarate, malate, and glutamine were decreased by Bevacizumab treatment in the tumors. By the treatment of Glutaminase(GLS) inhibitor, citrate, pyruvate, succinate, fumarate, malate, glutamine, and lactate were decreased in the tumors. By the treatment of both Bevacizumab and GLS inhibitor, citrate, pyruvate, succinate, fumarate, malate, glutamine, and lactate were decreased. Dual treatment induced significant inhibition of TCA cycle. In vitro experiment, U87 cell proliferation was inhibited by dual treatmet (bevacizumab + GLS inhibitor). Finally, in vivo experiment, Bevacizumab treatment had significant longer survival than control. However, dual treatment (Bevacizumab and GLS inhibitor) did not have longer survival than Bevacizumab alone.
|
